Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Novartis (SWX:NOVN) is expanding its late stage pipeline through acquisitions, highlighted by the recent purchase of Avidity Biosciences.
The Avidity deal brings three late stage genetic disorder therapies into the company’s portfolio at a time of industry wide patent cliffs and generic competition.
Novartis is also working with Genedata on an AI native R&D data platform to support drug discovery and development productivity.
For you as an investor, this combination of deal making and AI focused R&D is reshaping how Novartis approaches growth. The company is known for prescription medicines and specialty therapies and is now adding late stage genetic disorder programs while trying to manage the same patent expiry pressures affecting much of big pharma.
Attention will likely stay on how efficiently Novartis integrates the Avidity assets and uses the Genedata platform to move candidates through development. The balance between acquiring external programs and building internal AI capabilities may influence the company’s competitive position as new therapies come to market and older products face generic erosion.
Stay updated on the most important news stories for Novartis by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novartis.
SWX:NOVN Earnings & Revenue Growth as at Apr 2026
We’ve flagged 1 risk for Novartis. See which could impact your investment.
For investors, the Avidity acquisition and the AI-focused partnership with Genedata sit against a backdrop of softer near term numbers. Q1 2026 net sales were US$13,113m compared with US$13,233m a year earlier, and net income was US$3,156m versus US$3,606m. Management still reaffirmed 2026 guidance for low single digit net sales growth and a low single digit decline in core operating income, which suggests the heavier R&D spend and deal activity are already factored into the current outlook. Larger peers such as Pfizer, Merck and Roche are also using deals and late stage assets to refresh their pipelines as older products face generic pressure, so this approach keeps Novartis in step with the wider sector. The key question for you is whether the added late stage programs, AI-powered R&D efficiency and recent approvals like Rhapsido and Coartem Baby offset the current pressure from US generic erosion and higher R&D costs.
How This Fits Into The Novartis Narrative
The stepped up acquisitions and AI-native data platform align with the narrative that future growth is supported by advanced therapies and productivity gains in R&D and manufacturing.
Higher spending on late stage biotech deals and internal platforms could weigh on margins in the short term, which may challenge expectations for margin expansion if cost savings do not keep pace.
The narrative highlights advanced therapies and emerging markets but gives less attention to how AI-driven chemistry, manufacturing and controls platforms might affect regulatory timelines and capital efficiency.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Novartis to help decide what it’s worth to you.
The Risks and Rewards Investors Should Consider
⚠️ Higher R&D and acquisition spending, including potential monthly outlays of up to US$70m on the Avidity pipeline, can pressure profit margins and stretch the balance sheet if returns take time to materialize.
⚠️ Generic erosion in the US for drugs such as Entresto, Promacta and Tasigna, together with industry wide patent cliffs, increases the risk that older products lose share faster than new ones contribute.
🎁 The Avidity deal adds three late stage genetic disorder therapies and complements approvals like Rhapsido and progress in IgA nephropathy, which broadens the portfolio across immunology, neurology and rare disease.
🎁 The award winning AI-native R&D and CMC platform built with Genedata aims to turn fragmented development data into reusable assets, which may support faster, more efficient regulatory filings across the pipeline.
What To Watch Going Forward
From here, keep an eye on how quickly Avidity’s late stage programs progress, any updates on additional biotech deals, and concrete examples of time or cost savings from the Genedata AI platform. Track whether new launches such as Rhapsido and future gene or renal therapies offset pressure from US generics, and how this shows up in net sales and core operating income against the reaffirmed 2026 guidance. Analysts have flagged both rewards and one important risk for Novartis, so watching execution on integration, R&D productivity and capital allocation can help you judge whether the current acquisition and AI push is translating into a more resilient portfolio.
To ensure you’re always in the loop on how the latest news impacts the investment narrative for Novartis, head to the community page for Novartis to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVN.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com